inations of agents, generic and/or proprietary to the company or others, delivered locally and intra-operatively to the site of any medical or surgical procedure. As of February 15, 2012, its patent portfolio included 15 U.S. and 35 foreign issued or allowed patents, and 7 U.S. and 20 foreign pending patent applications, directed to its PharmacoSurgery product candidates and development programs. The company’s issued PharmacoSurgery patents have terms that would expire as late as September 24, 2022 for OMS103HP; August 4, 2032 for OMS103HP; July 30, 2023 for OMS302; and March 17, 2026 for OMS201. History Omeros Corporation was founded in 1994.